Novartis AG (NVSN) - Total Liabilities

Latest as of March 2026: MX$79.61 Billion MXN ≈ $4.58 Billion USD

Based on the latest financial reports, Novartis AG (NVSN) has total liabilities worth MX$79.61 Billion MXN (≈ $4.58 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Novartis AG long-term investment intensity to see how much of total assets are deployed in long-term investments.

Novartis AG - Total Liabilities Trend (2014–2025)

This chart illustrates how Novartis AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NVSN total asset value.

Novartis AG Competitors by Total Liabilities

The table below lists competitors of Novartis AG ranked by their total liabilities.

Company	Country	Total Liabilities
Royal Bank of Canada TO:RY	Canada	CA$2.35 Trillion
AstraZeneca PLC NASDAQ:AZN	USA	$66.63 Billion
Novartis AG ADR NYSE:NVS	USA	$80.09 Billion
China Construction Bank Corporation F:C6T	Germany	€43.49 Trillion
RTX Corporation NYSE:RTX	USA	$105.83 Billion
Roche Holding AG SW:ROG	Switzerland	CHF62.82 Billion
Toyota Motor Corporation ADR NYSE:TM	USA	$62.39 Trillion
GE Vernova LLC NYSE:GEV	USA	$60.55 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Novartis AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NVSN net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.85	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.67	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novartis AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novartis AG (2014–2025)

The table below shows the annual total liabilities of Novartis AG from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	MX$64.40 Billion ≈ $3.71 Billion	+10.81%
2024-12-31	MX$58.12 Billion ≈ $3.34 Billion	+9.26%
2023-12-31	MX$53.20 Billion ≈ $3.06 Billion	-8.33%
2022-12-31	MX$58.03 Billion ≈ $3.34 Billion	-9.29%
2021-12-31	MX$63.97 Billion ≈ $3.68 Billion	-15.15%
2020-12-31	MX$75.39 Billion ≈ $4.34 Billion	+20.02%
2019-12-31	MX$62.82 Billion ≈ $3.62 Billion	-6.06%
2018-12-31	MX$66.87 Billion ≈ $3.85 Billion	+13.63%
2017-12-31	MX$58.85 Billion ≈ $3.39 Billion	+6.55%
2016-12-31	MX$55.23 Billion ≈ $3.18 Billion	+1.47%
2015-12-31	MX$54.43 Billion ≈ $3.13 Billion	-0.20%
2014-12-31	MX$54.54 Billion ≈ $3.14 Billion	--

About Novartis AG

MX:NVSN Mexico Drug Manufacturers - General

Market Cap

$265.74 Billion

MX$4.62 Trillion MXN

Market Cap Rank

#69 Global

#3 in Mexico

Share Price

MX$2420.00

Change (1 day)

+1.85%

52-Week Range

MX$2254.90 - MX$2866.83

All Time High

MX$2866.83